The novel MEK inhibitor atebimetinib in combination with modified gemcitabine/nab-paclitaxel led to a 12-month overall ...

A former prostate cancer patient who got the all-clear said taking part in a trial that cut his radiotherapy treatments ...

Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population. A post-hoc ...

A large team of researchers led by Wouter Karthaus, head of the Endocrine Therapy Resistance and Molecular Genetics Lab at ...

A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment ...

Join Tom and Mike as they share an important update on Tom's prostate cancer journey. In this video, they discuss Tom's ...

Scientists at EPFL and Johns Hopkins uncover the central role of an enzyme in controlling prostate cancer subtypes and ...

DelveInsight's Castration-sensitive Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, CSPC emerging drugs, market share of individual ...

Curium’s Investigational New Drug (IND) application for 177Lu-PSMA-I&T, a therapeutic agent for patients with metastatic ...

An 82-year-old former TV presenter who still plays the drums in the West Midlands after successful cancer treatment is ...

As Novartis turns the calendar on a new year, the Swiss drugmaker is elaborating further on plans for the $23 billion U.S.